

Julien Kirchgesner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3503795/publications.pdf>

Version: 2024-02-01

63
papers

2,432
citations

304602

22
h-index

214721

47
g-index

64
all docs

64
docs citations

64
times ranked

3051
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Recurrent Acute Arterial Events Associated With Thiopurines and Anti-Tumor Necrosis Factor in Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 164-172.e11.	2.4	4
2	Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 218-225.	0.9	11
3	Calibrating Real-World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 179-186.	2.3	5
4	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e345.	2.4	0
5	Emulation of a randomized controlled trial in ulcerative colitis with <scp>US</scp> and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 167-175.	0.9	5
6	Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 314-324.e16.	2.4	27
7	Impact of Anti-tumour Necrosis Factor Agents on the Risk of Colorectal Cancer in Patients with Ulcerative Colitis: Nationwide French Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 893-899.	0.6	12
8	Risk of acute arterial events associated with treatment of inflammatory bowel diseases: a nationwide Danish cohort study. <i>Gut</i> , 2022, 71, 2373-2374.	6.1	2
9	Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study. <i>BMJ, The</i> , 2022, 376, e066192.	3.0	9
10	Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	1
11	Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case-Control Study Based on the French National Health Data System (SNDS). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 662-669.	1.1	9
12	Genital warts and inflammatory bowel diseases: Danish real-world evidence to assess patient-relevant outcomes. <i>United European Gastroenterology Journal</i> , 2022, 10, 249-250.	1.6	0
13	Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. <i>Gut</i> , 2022, 71, 1781-1789.	6.1	11
14	Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. <i>Digestive and Liver Disease</i> , 2022, 54, 1350-1357.	0.4	0
15	Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer. <i>Gut Microbes</i> , 2022, 14, .	4.3	20
16	Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 857-868.	1.9	5
17	A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1602-1610.e1.	2.4	26
18	Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. <i>Digestive and Liver Disease</i> , 2021, 53, 434-441.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 312-319.	1.9	26
20	Intraoperative random biopsies of strictureplasty sites can detect early small-bowel adenocarcinoma in patients with Crohn's disease. <i>Digestive and Liver Disease</i> , 2021, 53, 924-926.	0.4	2
21	Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 944-951.	1.9	24
22	Chronic pouchitis and Crohn's disease of the pouch after ileal pouch-anal anastomosis: Incidence and risk factors. <i>Digestive and Liver Disease</i> , 2021, 53, 1128-1135.	0.4	8
23	Prospective evaluation of third-generation small bowel capsule endoscopy videos by independent readers demonstrates poor reproducibility of cleanliness classifications. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101612.	0.7	14
24	The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 766-773.	0.6	11
25	Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 150-157.e1.	2.4	23
26	Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. <i>Gut</i> , 2020, 69, 852-858.	6.1	46
27	Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 449-457.	0.8	66
28	The impact of body composition parameters on severe toxicity of nivolumab. <i>European Journal of Cancer</i> , 2020, 124, 170-177.	1.3	32
29	Impact of Aphthous Colitis at Diagnosis on Crohn's Disease Outcomes. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 342-350.	0.6	2
30	Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. <i>United European Gastroenterology Journal</i> , 2020, 8, 303-313.	1.6	79
31	The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab. <i>Digestive and Liver Disease</i> , 2020, 52, 1148-1155.	0.4	13
32	Drastic decrease of urgent endoscopies outside regular working hours during the Covid-19 pandemic in the paris area. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 579-585.	0.7	9
33	Paving the way towards a weight loss intervention study in obese patients with inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 1143-1144.	1.6	2
34	Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID. <i>American Journal of Gastroenterology</i> , 2020, 115, 1812-1820.	0.2	50
35	Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1222-1230.	0.6	10
36	Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1324-1335.e2.	2.4	72

#	ARTICLE	IF	CITATIONS
37	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 896-903.	0.6	12
38	Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. <i>Microbiome</i> , 2020, 8, 12.	4.9	203
39	Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1096-1104.	1.9	19
40	The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumor necrosis factor. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 948-957.	1.9	84
41	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	0.8	19
42	Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 370-379.	2.4	63
43	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 892-899.e2.	2.4	80
44	Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. <i>Gut</i> , 2018, 67, 1261-1268.	6.1	104
45	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and <i>Clostridium difficile</i> infection. <i>Gut Microbes</i> , 2018, 9, 55-60.	4.3	85
46	Young GI angle: Planning the statistical analysis of the results. <i>United European Gastroenterology Journal</i> , 2018, 6, 1598-1600.	1.6	0
47	Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2018, 13, e0201991.	1.1	29
48	Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 337-346.e10.	0.6	411
49	Antioxidant trace elements serum levels in long-term parenteral nutrition (PN): Prevalence and infectious risk associated with deficiencies, a retrospective study from a tertiary home-PN center. <i>Clinical Nutrition</i> , 2017, 36, 812-817.	2.3	13
50	Autoimmune cytopenias associated with inflammatory bowel diseases: Insights from a multicenter retrospective cohort. <i>Digestive and Liver Disease</i> , 2017, 49, 397-404.	0.4	27
51	<i>Clostridium difficile</i> infection in acute flares of inflammatory bowel disease: A prospective study. <i>Digestive and Liver Disease</i> , 2017, 49, 643-646.	0.4	57
52	Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 930-935.	0.6	34
53	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1077-1084.	1.9	23
54	Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1679.	3.8	424

#	ARTICLE	IF	CITATIONS
55	Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 37-49.	1.9	77
56	Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. <i>PLoS ONE</i> , 2016, 11, e0157191.	1.1	19
57	1120 Incidence and Risk Factors of Serious Viral Infections in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S225.	0.6	0
58	Mo1852 Impact of Fertility Treatment on Inflammatory Bowel Disease Outcomes. <i>Gastroenterology</i> , 2016, 150, S795.	0.6	0
59	Editorial: mongsersen in Crohn's disease - a new contribution to the beginning of a long-awaited therapeutic revolution?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 838-839.	1.9	0
60	Azathioprine May Not be Associated With Development of Colorectal Tumors With Microsatellite Instability in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 149-151.	0.2	8
61	Pancreatic neuroendocrine tumor mimicking a malignant intraductal papillary mucinous neoplasm. <i>Pancreatology</i> , 2016, 16, 290-292.	0.5	1
62	Sa1118 Withdrawing or Continuing Maintenance Treatment With Thiopurines in Patients With Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. <i>Gastroenterology</i> , 2015, 148, S-231.	0.6	2
63	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and <i>Clostridium difficile</i> infection. , 0, .		1